Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer
- 1 March 1990
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 16 (3) , 167-170
- https://doi.org/10.1007/bf01724796
Abstract
We analyzed the haemodynamic effects of high doses of r-Met Hu IL-2 [ala-125] in four patients with advanced cancer. Haemodynamic parameters were measured daily from days 1 to 6 of treatment. Mean arterial pressure decreased significantly (98±11 mmHg on day 1 versus 84±7 mmHg on day 5;p=0.0435) as did systemic vascular resistance (2042±296 dynes s cm−5 m−2 on day 1 versus 1166±87 dynes s cm−5 m−2 on day 5;p=0.003). There was a significant increase in mean pulmonary artery pressure (13.25±3.30 mmHg on day 1 versus 20.75±7.41 mmHg on day 5;p=0.03), systemic oxygen consumption (173.5±37.8 ml min−1 m−2 on day 1 versus 257.8±20.5 ml min−1 m−2 on day 5;p=0.02) and cardiac index (3.86±0.58 l min−1 m−2 on day 1 versus 5.77±0.21 l min−1 m−2 on day 5;p=0.008). There was no significant decrease in the arteriovenous oxygen content difference (4.5±0.8 ml dl−1 on day 1 versus 4.46±0.22 ml dl−1 on day 5). Increases in oxygen delivery (570±163 ml min−1 m−2 on day 1 versus 750±109 ml min−1 m−2 on day 5 and oxygen extraction ratio (29.95%±6.37% on day 1 versus 34.60%±4.35% on day 5) were not statistically significant. We concluded that the haemodynamic effect induced by high doses of r Hu-IL-2 is similar to that seen in septic shock.Keywords
This publication has 18 references indexed in Scilit:
- The Rapid Induction by Interleukin-2 of Pulmonary Microvascular PermeabilityAnnals of Surgery, 1989
- Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2Annals of Internal Medicine, 1988
- Review: Cardiopulmonary Toxicity of Adoptive ImmunotherapyThe Lancet Healthy Longevity, 1988
- Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJournal of Clinical Immunology, 1988
- Multiple organ failure during interleukin-2 administration and LAK cells infusionIntensive Care Medicine, 1988
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- New Approaches to the Immunotherapy of Cancer Using Interleukin-2Annals of Internal Medicine, 1988
- Increased Vascular Permeability in Organs Mediated by the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in MiceJNCI Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985